share_log

醫渡科技：翌日披露報表

YIDU TECH: Next Day Disclosure Return

Hong Kong Stock Exchange ·  Apr 17 07:00
Summary by Moomoo AI
醫渡科技有限公司於2024年4月17日進行了股份購回活動，根據香港聯合交易所有限公司證券上市規則披露，公司購回了146,100股普通股。該次股份購回佔公司於購回前已發行股份的0.0138%，購回價格範圍為每股3.39港元至3.48港元，總支付金額為500,670.09港元。此外，自普通決議案通過至今，公司在香港聯交所累計購回股份數目為845,300股，佔已發行股份的0.0803%。公司確認，所有相關法律文件已正式存檔，並且所有法律規定已遵守。
醫渡科技有限公司於2024年4月17日進行了股份購回活動，根據香港聯合交易所有限公司證券上市規則披露，公司購回了146,100股普通股。該次股份購回佔公司於購回前已發行股份的0.0138%，購回價格範圍為每股3.39港元至3.48港元，總支付金額為500,670.09港元。此外，自普通決議案通過至今，公司在香港聯交所累計購回股份數目為845,300股，佔已發行股份的0.0803%。公司確認，所有相關法律文件已正式存檔，並且所有法律規定已遵守。
On 17 April 2024, Medical Technology Co., Ltd. repurchased 146,100 shares of ordinary shares in accordance with the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited. The share buyback represents 0.0138% of the Company's shares issued prior to the repurchase. The repurchase price ranges from HK$3.39 to HK$3.48 per share for a total payment of HK$500,670.09. In addition, since the adoption of the Ordinary Resolution, the Company has accumulated a cumulative repurchase of 845,300 shares on the Hong Kong Stock Exchange, representing 0.0803% of the issued shares. The Company confirms that all relevant legal documents have been formally archived and that all legal requirements have been complied with.
On 17 April 2024, Medical Technology Co., Ltd. repurchased 146,100 shares of ordinary shares in accordance with the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited. The share buyback represents 0.0138% of the Company's shares issued prior to the repurchase. The repurchase price ranges from HK$3.39 to HK$3.48 per share for a total payment of HK$500,670.09. In addition, since the adoption of the Ordinary Resolution, the Company has accumulated a cumulative repurchase of 845,300 shares on the Hong Kong Stock Exchange, representing 0.0803% of the issued shares. The Company confirms that all relevant legal documents have been formally archived and that all legal requirements have been complied with.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more